IDEXX Laboratories, Inc. (IDXX)

In the past six months, IDEXX Laboratories' stock experienced an all-time high closing price of $766.68 on November 25, 2025. On February 2, 2026, the company reported its fourth-quarter and full-year 2025 results, showing 14% reported revenue growth and 12% organic growth. In January 2026, Jonathan Jay Mazelsky became President and CEO. On May 5, 2026, IDEXX announced its first-quarter 2026 results, reporting diluted earnings per share of $3.47 and revenue rising 14% to $1.14 billion. The company raised its full-year 2026 profit and revenue outlook. As of May 8, 2026, the stock price was $560.11, down around 15% year-to-date.

IDEXX Laboratories' business experiences normal seasonality, which can impact its financial results, including free cash flow. The company's annual report mentions the seasonality of certain product lines as a factor that can cause future operating results to vary significantly from quarter to quarter or year to year.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services for companion animal veterinary, livestock and poultry, water testing, and dairy markets. The company operates through three segments: Companion Animal Group (CAG), Water, and Livestock, Poultry and Dairy (LPD). The CAG segment provides in-clinic laboratory analyzers, diagnostic imaging, veterinary practice management software, and reference laboratories. The Water segment offers products to measure microbiological parameters in water. The LPD division provides diagnostic tests and services to detect diseases in livestock and poultry, as well as solutions for monitoring milk quality and herd health.

IDEXX Laboratories operates globally, serving customers in over 175 countries and territories. It has more than 80 reference laboratories, advanced manufacturing sites, and strategically located sales and distribution offices. North America is its largest market, while Europe is its most significant international region. The company also has a growing presence across Asia-Pacific and Latin America. Its headquarters are in Westbrook, Maine, U.S., and its European headquarters are in Hoofddorp, Netherlands.

IDEXX Laboratories has maintained a strong brand reputation, as evidenced by its inclusion in several Forbes lists for 2026, including America's Best Employers For Company Culture, America's Best Large Employers, and America's Best-In-State Companies for Laboratories-Veterinary. The company was also listed as one of America's Dream Employers for 2026.

IDEXX Laboratories, Inc. is primarily owned by institutional investors, who hold approximately 92.60% of shares. Insider ownership stands at 1.77%, with former CEO Jonathan W. Ayers being a significant individual stakeholder. Retail investors comprise the remaining 5.63% of the company's structure.